Changzhou Boyi Biotechnology

About Changzhou Boyi Biotechnology

Changzhou Boyi Biotechnology Co., Ltd. is a technology-focused enterprise centered on the in-vitro diagnostic industry. The company originated in 2013 as Changzhou Tiandi Renhe Biotechnology Co., Ltd., founded by a group of experts in polymer materials, proteomics, and molecular biology to focus on the purification of biological macromolecules. The Boyi Bio Group itself was established in 2022 and now owns brands such as Tiandi Renhe, Boyi Bio, and ACE. The chairman and general manager is Fang Li.

Boyi Biotechnology provides key raw materials and integrated solutions for biomedical clients. The business is structured around three main sectors: purification of biological macromolecules, core raw materials for in-vitro diagnostic reagents, and life science research reagents. The company's product lines include diagnostic microspheres, testing raw materials, and quality control products. Specifically, they produce a range of chromatography resins (gel filtration, affinity, ion exchange, hydrophobic interaction), magnetic beads, and various biological reagents and instruments under its ACE brand. These products are used in applications such as recombinant proteins, vaccines, antibodies, gene therapy, and cell therapy.

The company has made significant investments in its infrastructure, with a total project investment of RMB 300 million for a 45,000-square-meter facility in Changzhou's Xitaihu Industrial Park, which includes R&D, office, and production buildings with 10 automated production lines expected to be operational in the second half of 2024. Boyi Biotechnology has received recognition as a National High-tech Enterprise in 2019 and was named a provincial "Potential Unicorn" and "Gazelle" enterprise. As of early 2024, the company holds 6 authorized invention patents and 62 utility model patents. In July 2023, it successfully obtained ISO 13485:2016 certification for its medical device quality management system.